AAD 2026 Late-Breaking: RADIANT-AD One-Year Phase 3 Presentation

Connect Biopharma said in a GlobeNewswire press release that one-year Phase 3 results from Simcere’s atopic dermatitis program with RADIANT-AD will be presented as a Late-Breaking Research oral session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The release lists the session entry as “79594 - Rademikibart monotherapy in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD): A 1-year, phase III, randomized, double-blinded, placebo-controlled trial (RADIANT-AD),” scheduled for Saturday, March 28, 2026, from 9:48–10:00 a.m. MDT in Bellco Theatre 3 in Denver, Colorado. The announcement frames the AAD session as the setting where the company says the one-year findings will be disclosed.

In the release, the presentation is described as a one-year Phase 3 study of rademikibart monotherapy in adults and adolescents with moderate-to-severe atopic dermatitis. The company outlines the trial as randomized, double-blinded, and placebo-controlled, and notes the work was conducted by Simcere Pharmaceutical Co., Ltd., Connect’s partner in China.

The press release largely focuses on the scheduled presentation and meeting logistics, alongside a brief description of the study as a 1-year, phase III, randomized, double-blinded, placebo-controlled trial. It does not include numerical results, but does include company interpretation, including a statement from Connect’s CEO describing rademikibart’s “potentially differentiated safety and efficacy.” The statement also references Connect’s broader development priorities beyond atopic dermatitis, while the release itself does not provide underlying datasets.

The announcement also links the Phase 3 readout to regulatory and commercial items described in the release, including Simcere’s pending New Drug Application (NDA) for rademikibart in China. Connect reiterates that it granted Simcere an exclusive license for rademikibart in Greater China and states it is eligible for remaining milestone payments up to an aggregate amount of approximately $110 million upon certain development, regulatory, and commercial milestones, along with tiered royalties on net sales up to low double-digit percentages in the region. A forward-looking statements section characterizes expectations as projections subject to risks and uncertainties and notes the product candidate remains under clinical investigation. In the company’s framing, the upcoming AAD presentation sits within the described China NDA and licensing framework.

Key Takeaways:

• The press release says one-year Phase 3 RADIANT-AD results are slated for a Late-Breaking Research oral presentation at AAD 2026 in Denver.
• The announced talk is described as a one-year Phase 3, randomized, double-blinded, placebo-controlled monotherapy trial in adults and adolescents with moderate-to-severe atopic dermatitis.
• The company links the readout to Simcere’s pending China NDA and reiterates Greater China license terms, including approximately $110 million in remaining milestones and tiered net-sales royalties up to low double-digit percentages.